Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib (RESORCE)
Regorafenib
15982
NCT01774344
Hepatocellular carcinoma
Phase 3
 
October 2017

Powered by ideaPoint, Inc.